Lenvatinib Plus Pembrolizumab Shows Activity in Many Cancer Types

The ESMO 2020 Virtual Congress presented initial results from the LEAP-005 study, showing that previously treated advanced cancers respond to targeted therapy plus immunotherapy combination treatment (lenvatinib + pembrolizumab).
One year after lenvatinib plus pembrolizumab received approval for previously treated endometrial (uterine) cancer, the phase II LEAP-005 study suggests that other advanced cancers previously treated with multiple therapies are also likely to respond to this combination.
Lenvatinib (Lenvima) acts on the cell membrane's tyrosine kinase receptor, a receptor whose activity it blocks. Tyrosine kinase receptors generally play a role in cancer cell growth, proliferation, formation of new blood vessels, and spread to distant tissues. Lenvatinib previously received approval for thyroid cancer in 2015, kidney cancer in 2016, liver cancer in 2018, and uterine cancer in 2019 from the United States Food and Drug Administration (FDA).
Pembrolizumab (Keytruda) acts through the interaction of immune checkpoints that inactivate the immune system against cancer: PD-1 and PD-L1. A monoclonal antibody that binds to PD-1 and activates T cells, it is an immunotherapy drug. Pembrolizumab has so far received FDA approval in 16 different cancer types.
Details of the LEAP-005 study
- This open-label, multicenter study enrolled 187 patients with 6 different tumor types:
- triple-negative breast cancer,
- ovarian cancer,
- stomach cancer,
- colorectal (large intestine) cancer (without MSI-H or mismatch repair deficiency),
- glioblastoma multiforme (GBM) and
- biliary tract cancer (excluding ampullary tumors)
- Patients received 20 mg of lenvatinib daily plus 200 mg of pembrolizumab every 3 weeks.
- Treatment continued for 35 weeks, until confirmed disease progression, or until unacceptable side effects developed.
- Prior treatment histories were as follows: triple-negative breast cancer, 1 or 2 previous lines; ovarian cancer, 3 lines; stomach cancer, 2 lines; colorectal cancer, 2 lines; GBM, 1 line; and biliary tract cancer, 1 line of systemic therapy.
- The primary endpoints measured in the study were objective response rate and safety.
Results
- At the interim data analysis on 10 April 2020, median study follow-up was 8.6 months (range 1.9-13.1).
- Objective response rates by cancer type were:
- stomach cancer 10% (95% confidence interval [CI] 2-26)
- biliary tract cancer 10% (95% CI 2-26)
- GBM 16% (95% CI 6-34)
- colorectal cancer 22% (95% CI 9–40)
- triple-negative breast cancer 29% (95% CI 14-48), and
- ovarian cancer 32% (95% CI 17-51).
- Disease control rates
- were 48% in stomach cancer,
- 68% in biliary tract cancer,
- 58% in GBM,
- 47% in colorectal cancer,
- 58% in triple-negative breast cancer, and
- 74% in ovarian cancer.
- Among responders, median response duration was:
- 3.2 months in GBM,
- 5.3 months in biliary tract cancer, and had not been reached in the other cancer types.
- The longest median response duration observed was in a patient with colorectal cancer, at more than 10.4 months.
- Regarding side effects, those of lenvatinib + pembrolizumab were found manageable. Serious (grade 3) treatment-related side effects were most common in the ovarian cancer group (68%) and least common in the GBM group (35%). Grade 3 side-effect rates in the other tumor types were 42% in stomach cancer, 48% in biliary tract cancer, 50% in colorectal cancer, and 55% in triple-negative breast cancer. Treatment-related side effects led to treatment discontinuation most frequently in the ovarian cancer group (13%), followed by triple-negative breast cancer (10%) and colorectal cancer (9%); all three remaining groups had a 6% discontinuation rate.
Given the promising data for this combination in previously treated advanced solid-organ cancers, additional patient enrollment in all groups was reported to have been agreed.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.